← Back to Clinical Trials
Recruiting NCT07492004

NCT07492004 China Monogenic Diabetes Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07492004
Status Recruiting
Phase
Sponsor Tianjin Medical University General Hospital
Condition Neonatal Diabetes
Study Type OBSERVATIONAL
Enrollment 5,000 participants
Start Date 2021-02-28
Primary Completion 2030-07-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 5,000 participants in total. It began in 2021-02-28 with a primary completion date of 2030-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to: Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution Participants will: * Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis

Eligibility Criteria

Inclusion Criteria: 1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age 2. Body mass index (BMI) at diagnosis 28 kg/m² 3. Negative glutamic acid decarboxylase antibody (GAD-Ab) Exclusion Criteria: 1. Secondary diabetes 2. Active malignancy or history of malignant tumor within the past 5 years

Contact & Investigator

Central Contact

Ming Liu

✉ mingliu@tmu.edu.cn

📞 +86 022-27813550

Frequently Asked Questions

Who can join the NCT07492004 clinical trial?

This trial is open to participants of all sexes, studying Neonatal Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07492004 currently recruiting?

Yes, NCT07492004 is actively recruiting participants. Contact the research team at mingliu@tmu.edu.cn for enrollment information.

Where is the NCT07492004 trial being conducted?

This trial is being conducted at Tianjin, China.

Who is sponsoring the NCT07492004 clinical trial?

NCT07492004 is sponsored by Tianjin Medical University General Hospital. The trial plans to enroll 5,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology